Clinical trials: Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumors
Laparoscopic Endoscopic Cooperative Surgery in the Treatment of Gastric Stromal Tumors
Gastrointestinal stromal tumor (GIST) is a kind of mesenchymal tumor with malignant differentiation potential. It originated from mesenchymal stem cells of gastrointestinal tract.The most common is that gastric stromal…
- Trial name
- LECSINGST (NCT03601234)
- Testing
- laparoscopic and endoscopic cooperative surgery, laparoscopic surgery
- Where
- China
- Volunteers
- 80 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Stomach Cancer, Gastric (Stomach) Cancer
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
To investigate bevacizumab in combination with carboplatin and capecitabine for patients with unresectable or metastatic GEJ or gastric cancers.
- Conditions
- Stomach Cancer, Gastric (Stomach) Cancer, Neoplasm of Cardioesophageal Junction, Gastrointestinal Stromal Tumor (GIST)
- Trial name
- NCT00780494
- Testing
- bevacizumab, carboplatin, capecitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Stanford University
Gastrointestinal Stromal Tumors (GISTs)
L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors
we aim to evaluate the efficacy of L-carnitine for the treatment of muscle cramps after imatinib in patients with GIST and apply in the future.
- Trial name
- NCT03426722
- Testing
- L-carnitine
- Where
- South Korea
- Volunteers
- 4 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumors
The Correlation Between Ripretinib Exposure and the Efficacy and Safety in Patients with Advanced GISTs
This is a prospective, single-center, observational study to explore the correlation between ripretinib exposure and the efficacy and safety in patients with advanced gastrointestinal stromal tumors
- Trial name
- NCT06431451
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Gastrointestinal Stromal Tumors
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
This trial was a Phase I/II, non-randomized, open label, multi-center study, following a sequential 2-part design.
- Trial name
- NCT01275222
- Testing
- RAD001, Imatinib 600mg/day (Glevec is the brand name for imatinib), Imatinib 800mg/day (Glevec is the brand name for imatinib)
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Carcinomatosis, Peritoneal, Pancreas Cancer
Characterization of Biophysical Stromal Properties in Human Cancer: Towards Personalized Computational Oncology
Drug delivery in solid tumors, whether administered systemically or locoregionally, is hindered by an elevated interstitial fluid pressure (IFP).
- Conditions
- Carcinomatosis, Peritoneal, Pancreas Cancer, Ovarian Cancer, Colon Cancer
- Trial name
- DCE-MRI (NCT04512209)
- Testing
- MRI
- Where
- Belgium
- Volunteers
- 22 people
- Sponsor
- University Hospital, Ghent
Gastrointestinal Stromal Tumor (GIST)
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
This study is being done to gather information about the safety (any harmful effects) and effectiveness (usefulness) of Pazopanib in the treatment of Gastrointestinal Stroma Tumors (GIST) that cannot be treated by surgery or has…
- Trial name
- NCT01391611
- Testing
- Pazopanib
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Kristen Ganjoo
Gastrointestinal Stromal Tumor
Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
The purpose of this research study is to determine the safety and tolerability of sunitinib alternating with regorafenib in participants with advanced gastrointestinal stromal tumor GIST, if the standard approved therapies…
- Trial name
- SURE (NCT02164240)
- Testing
- Sunitinib, Regorafenib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction
Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction
RATIONALE: The use of endoscopy to place a metal stent in the large intestine is less invasive than surgery for treating cancer-related bowel obstruction and may have fewer side effects and improve recovery.
- Conditions
- Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Gastric Cancer, Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00004911
- Testing
- bowel obstruction management, quality-of-life assessment
- Where
- United States
- Sponsor
- Northwestern University
Gastrointestinal Stromal Tumor, Stage III Soft Tissue Sarcoma
Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
This phase I trial studies the side effects and best dose of dasatinib when given together with ipilimumab in treating patients with gastrointestinal stromal tumors or other sarcomas that cannot be removed by surgery or have…
- Conditions
- Gastrointestinal Stromal Tumor, Stage III Soft Tissue Sarcoma, Stage IV Soft Tissue Sarcoma
- Trial name
- NCT01643278
- Testing
- Dasatinib, Ipilimumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumors, Unresectable Solid Tumor
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA
This is a prospective, multicenter, observational real-world study to explore the Avapritinib therapy in GIST patients who definited Non-exon18 Mutations of PDGFRA.
- Conditions
- Gastrointestinal Stromal Tumors, Unresectable Solid Tumor, Recurrent Metastatic Malignant Neoplasm
- Trial name
- NCT05461664
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Xinhua Zhang, MD
Tumor Pathway Activations Inhibited by Dovitinib
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further…
- Trial name
- SIGNATURE (NCT01831726)
- Testing
- Dovitinib (TKI258)
- Where
- 49 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Neoplasms
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug…
- Trial name
- NCT07218926
- Testing
- IDRX-42, Sunitinib
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline
Pancreatic Cancer, Colorectal Cancer
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
This is a Phase 1 multi-center study to assess the safety and efficacy of TGR-1202 as a single agent or in combination with nab-paclitaxel + gemcitabine or with FOLFOX in patients with select relapsed or refractory solid tumors.
- Conditions
- Pancreatic Cancer, Colorectal Cancer, Rectal Cancer, Gastric Cancer
- Trial name
- NCT02574663
- Testing
- TGR-1202, nab-paclitaxel + gemcitabine, Oxaliplatin + Folinic acid + Fluorouracil
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- TG Therapeutics, Inc.
Gastrointestinal Stromal Tumors
Rechallenge of Imatinib in GIST Having no Effective Treatment: RIGHT
The objective of this study is to compare the clinical outcomes following resumption of dosing (re-challenge) with Imatinib plus best supportive care versus placebo plus best supportive care in patients with advanced/incurable…
- Trial name
- NCT01151852
- Testing
- Imatinib
- Where
- South Korea
- Volunteers
- 81 people
- Sponsor
- Asan Medical Center